FDA extends review on Dynavax's Heplisav-B, but management remains confident
admin 4th August 2017 Uncategorised 0The future of hepatitis B vaccine candidate Heplisav-B has sent developer Dynavax’s shares, and its investors, on a wild ride. A recent request by the FDA for more details of the vaccine’s postmarketing surveillance plan sent its stock slightly downward, but both management and analysts said they remain confident in approval.
More: FDA extends review on Dynavax's Heplisav-B, but management remains confident
Source: fierce